iiinova — where your digital self keeps evolving

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

8/ Future trials must fix the usual pitfalls: 🚩 Phenotype enrichment (LVH, high K gradient, volume overload) 🚩 Blinded adjudication 🚩Explicit competing-risk modeling 🚩Patient burden metrics #Nephsky

130 3

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

6/ Incremental dialysis may “preserve RRF,” but current evidence is observational, biased, and non‑adjudicated. Healthier patients are selected, not randomized. CV benefit is unproven. Only high‑RRF incident patients with strict monitoring fit the strategy

111 1

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

2/ High-volume HDF shows the strongest survival signal - but we must stay critical. Prior trials had center effects, adherence bias, and achieved-dose confounding. CONVINCE helps, but the mechanism remains opaque www.nephjc.com/news/convince

120 2

Cristina Popa @nephroseeker.medsky.social · 03/10/2026

Dialysis adequacy MUST move beyond urea kinetics, and some of us have stated this for years. 🫀The dominant threat is cardiovascular stress: volumes, electrolytes, arrhythmia, LV load, inflammation... Kt/V is not enough #Nephsky academic.oup.com/ndt/advance-...

163 6

Cristina Popa @nephroseeker.medsky.social · 26/06/2026

💡Nephrology inpatient volume increased 44%, outpacing other specialties ⏮️ Retrospective, 62 million admissions over 10 yrs 📍Patients became more complex: ⬆️multidisciplinary care, frailty& poorer primary care access 📍Complexity increased mainly independent of aging www.ajkd.org/article/S027...

031 3

Cristina Popa @nephroseeker.medsky.social · 02/06/2026

Here the #ERA26 starts! ❤️🫶Perfect welcome and room view for kidney docs

010 1

Cristina Popa @nephroseeker.medsky.social · 16/05/2026

Interesting case of an unusual cause of hyperkalemia in a patient on chronic hemodialysis 💌 Don’t eat pickled cactus for breakfast 🌵 jamanetwork.com/journals/jam...

1115 11

Cristina Popa @nephroseeker.medsky.social · 25/04/2026

4/5 Critical caveat: the MDR classification relies on breakpoints borrowed from related genera — no Psychrobacter-specific clinical standards exist. ⚠️Gene presence ≠ confirmed expression ⚠️The mcr-1 finding needs independent verification to rule out contamination

120 2

Cristina Popa @nephroseeker.medsky.social · 25/04/2026

3/5 The strain inhibited 14 ESKAPE pathogens, including MRSA, K. pneumoniae, and P. aeruginosa. It carries biosynthetic genes for glycopeptides and bacitracin‑like products. A both antibiotic‑resistant and antimicrobial‑producing - ecologically coherent and medically intriguing.

110 1

Cristina Popa @nephroseeker.medsky.social · 25/04/2026

2/5 SC65A.3 was isolated from Scarisoara Ice Cave's perennial ice block. Whole genome sequencing identified >100 antimicrobial resistance-associated genes, including mcr-1 (colistin), ampC (beta-lactams), and fluoroquinolone resistance determinants ⚠️No modern antibiotic exposure

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

14/ Last but not least- jet-lagged night walks, sharing a Pikachu 🍫, and drawing omikuji paper fortunes at a Buddhist temple. Small moments turning into memories, that keep us close long after the meeting ends #ISNWCN @drbarbateba.bsky.social @arunkumarnephro.bsky.social @hswapnil.medsky.social

130 3

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

13/ SoMe team met with the Emerging Leaders party #ISNWCN

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

12/ Meeting for the first time in person, while we were in the same #NSMC cohort (almost 4 years ago) #ISNWCN

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

10/ One of the charms of #ISNWCN was randomly bumping into so many inspiring persons. * I still didn't found all the pictures fitting into this chaper @rosertorra.bsky.social @priti899.bsky.social

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

9/ Not quite myself for a bit at ISN - even arrived very late to the Emerging Leaders program. Still grateful to be there, inspired by the previous generation, generous mentors, and my Cohort 4 colleagues. #ISNWCN

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

8/ Divya Bajpai and I were minutes from getting locked in a conference room at 10:30 pm the night before, while working on our presentation #ISNWCN 🌞The next day: our spotlight session on senior vs junior perspectives on social media in clinical practice and education

120 2

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

7/ Participated in Kidney Tank. I’ll let you guess the hour; I'll just say we won. Tough brief, time crunch, tech issues, and jet lag, so we leaned on creativity and each other. Learned a lot about where social media in nephrology is heading #ISNWCN @theisn.org

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

6/ Second time meeting in person- and still thinking how much I’ve learned from @lastwalsh.bsky.social over the past nine months through the RADIANT program. Grateful for the guidance and the perspective #ISNWCN

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

4/ Live-covering late-breaking clinical trials with one of the OGs. And in between, the kind of thoughtful conversations where he quietly points out what I would have otherwise missed #ISNWCN

110 1

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

3/ #NephJC holds a special place in many ❤️- a space where learning stays open, ideas move freely, and friendships form across borders and career stages. #NephJC brings people together on equal ground @hswapnil.medsky.social @juancarlosqvelez.bsky.social @drbarbateba.bsky.social

141 4

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

2/ Being part of the #ISNWCN social media team was energizing. Meeting some people for the first time, reconnecting with others I already knew, and learning throughout, it made me appreciate our community even more. Grateful to help amplify it

131 3

Cristina Popa @nephroseeker.medsky.social · 07/04/2026

35 hours of travel to reach #ISNWCN, and every second was worth it. Standing here, surrounded by colleagues and friends from across the world, the only feeling is privilege - grateful to have made it, grateful to learn, grateful to share this space with a global kidney community ✨My short recap

174 7

Cristina Popa @nephroseeker.medsky.social · 25/03/2026

✨ Turning trial results into real‑world kidney care: methods, value, digital health #ISNWCN 🎯A sharp session on the science of making change happen 🎤 Tae Won Yi, rukshanashroff.bsky.social, Yusuke Sakaguchi, Meg Jardine

030 3

Cristina Popa @nephroseeker.medsky.social · 25/03/2026

🔧 Implementation science is the missing link between evidence and reality #ISNWCN 👍From hands‑on methods to digital health trials, this session shows how we turn ideas into impact 🌸A must‑see for anyone 🎙️Megumi Oshima, Robert Kalyesubula, Shuchi Anand, Adeera Levin, Bill Wang

030 3

Cristina Popa @nephroseeker.medsky.social · 25/03/2026

🚀 Clinical trials and kidney research are evolving fast 🌐 From global trial design to inclusivity, novel tools, and cross‑border collab, this upcoming #ISNWCN session is packed with ideas shaping our next decade 🎙️ Adeera Levin, Andrea Viecelli, Rathika Krishnasamy, Pedro Henrique Franca Gois

021 2

Cristina Popa @nephroseeker.medsky.social · 25/02/2026

We spend our money here on this 👇😅, and, even some HIF-PHI are approved by EMA, we don't have them. #NephJC

030 3

Cristina Popa @nephroseeker.medsky.social · 25/02/2026

Yes, agree. Some logistics to be considered. IN Europe, some iron forms are more expensive than EPO (Ferinject is the iron we give in my unit, so when I negotiate with the people in charge, I usually say that I'll cut down EPO) #NephJC

041 4

Cristina Popa @nephroseeker.medsky.social · 25/02/2026

Cristina Popa, Romanian nephrologist—4 am and implicitly sleepy and partially responsible for my reasoning #nephjc Pic somewhere in Italy; my playlist to keep me awake is French, except for “Iron sky” ☁️ to align with the topic tonight and with the state of things youtu.be/ELKbtFljucQ?...

060 6

Cristina Popa @nephroseeker.medsky.social · 11/02/2026

Hmm... mechanistic and safety studies tend to be short. CONFIDENCE trial had about 24 weeks, MIRO-CKD also 12 weeks #NephJC

042 4

Cristina Popa @nephroseeker.medsky.social · 11/02/2026

Hi! Cristina Popa, 🇷🇴 nephrologist. No COIs, than obvious #flozinator Sleepy and lurking 💤 Pic from 2 days ago (when on call) #NephJC

260 6

Cristina Popa @nephroseeker.medsky.social · 14/01/2026

Cristina Popa, Romanian nephrologist, no COI #NephJC Super sleepy, 4 am 👉 lurking Started gathering all the Christmas decorations, with these guys 😀

2100 10

Cristina Popa @nephroseeker.medsky.social · 17/12/2025

Welcome to our clinic, @hswapnil.medsky.social 😅 There is no chronic prescription in AKI

120 2

Cristina Popa @nephroseeker.medsky.social · 17/12/2025

Yes! Creatinine is 🐌🐌🐌 We dialyse humans, not labs #NephJC

111 1

Cristina Popa @nephroseeker.medsky.social · 17/12/2025

Hi! Cristina Popa here 👋 #NephJC No COIs. Never practiced 3xHD per week in AKI It’s harder to be awake at this hour when on vacation (although it’s only 3 am 🥱). Here are some pics👇

070 7

Cristina Popa @nephroseeker.medsky.social · 03/12/2025

#nephjc The sensitivity analyses even have "poisson" in it, which is French for fish 🐟 😀

171 7

Cristina Popa @nephroseeker.medsky.social · 03/12/2025

The most fishy thing is how all components of the primary outcomes are positive #nephjc Almost unheard in dialysis...

260 6

Cristina Popa @nephroseeker.medsky.social · 03/12/2025

That's surprising for all of us... Given the desert of positive trials in dialysis #nephjc

231 3

Cristina Popa @nephroseeker.medsky.social · 03/12/2025

🌽 oil- is debatable, but it seems "more neutral" for CV than other types of oils #NephJC pubmed.ncbi.nlm.nih.gov/33853582/

131 3

Cristina Popa @nephroseeker.medsky.social · 03/12/2025

Hi, #NephJC Cristina Popa, 🇷🇴 nephrologist 💤4 am on my timezone, a bit sleepy, but the fishy smell will keep me awake 🎄Pics from my last weekend trip to Bucharest

081 8

Cristina Popa @nephroseeker.medsky.social · 25/11/2025

Probably #nephsky will never see a trial comparing spironolactone with finerenone Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials pubmed.ncbi.nlm.nih.gov/41173939/

372 7

Cristina Popa @nephroseeker.medsky.social · 19/11/2025

Hi! I'm Cristina Popa, 🇷🇴 nephrologist #NephC No COI Mainly lurking tonight 👇 Pic from my city, called Iasi (borrowed)

040 4

Cristina Popa @nephroseeker.medsky.social · 06/11/2025

While having FOMO for not being at #KidneyWk , looking at the #NephMadness logo for 2026. Can’t wait for it 🤩

153 5

Cristina Popa @nephroseeker.medsky.social · 30/10/2025

For the sake of discussion, EMPA-KIDNEY (or any SGLT2i trial) excluded pts with serious immunosuppression... And since we look at subgroups, there is no difference in genital infections when accounting for primary kidney disease #nephjc pubmed.ncbi.nlm.nih.gov/38061372/

031 3

Cristina Popa @nephroseeker.medsky.social · 30/10/2025

2/ on the other side, some might say we have the poison and its antidote in the same bottle… Curious how 🇷🇴 is safer. As nephrologist, we have methanol intoxication seasonal clusters 😅 ourworldindata.org/alcohol-cons...

121 2

Cristina Popa @nephroseeker.medsky.social · 30/10/2025

1/ As a Romanian, and Eastern European this is funny to me- meaning by any ranking, my country has highest alcohol consumption worldwide. I grew up assisting my great grandparents preparing moonshine (main source of methanol), and learned how intoxication looks global-relocate.com/rankings/alc...

120 2

Cristina Popa @nephroseeker.medsky.social · 17/10/2025

🥲 Looking at published abstract for #KidneyWk this year, I realize I'll have a bigger FOMO than anticipated LBCTs - all sorts of them: posters: special sessions, right during plenary sessions @asnkidney.bsky.social why are u the only big nephro organization that doesn't have hybrid options?

160 6